NZ 598502 Disclosed is the use of a VEGF antagonist in the manufacture of a medicament for treating diabetic macular edema in a human by intravitreal administration. The disclosed VEGF antagonist is a protein antagonist, and wherein the medicament is formulated for administration in a method comprising: administering three first individual doses of the VEGF antagonist at one month intervals； followed by administering a number of second individual doses of the antagonist, wherein the second individual doses are administered less frequently than the first individual doses.
